Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria

Yazid Aoudia; Thitima Kongnakorn; Evie Merinopoulou; Mohamed Said Bettayeb; Sid Ahmed Kherraf

doi:10.36469/9797

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

JHEOR

Articles
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers

search
X (formerly Twitter) (opens in a new tab)
Bluesky (opens in a new tab)
LinkedIn (opens in a new tab)
RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:10467/feed

ISSN 2327-2236

Cardiovascular Conditions

Vol. 5, Issue 1, 2017

May 05, 2017 EDT

Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria

Yazid Aoudia, Thitima Kongnakorn, Evie Merinopoulou, Mohamed Said Bettayeb, Sid Ahmed Kherraf,

algeriaaspirinrivaroxabanacenocoumarolatrial fibrillationcost-effectivenessapixaban

ccby-4.0

• https://doi.org/10.36469/9797

JHEOR

Aoudia Y, Kongnakorn T, Merinopoulou E, Bettayeb MS, Kherraf SA. Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria. JHEOR. 2017;5(1):39-54. doi:10.36469/9797

View more stats